

# Rebecca Mercieca-Bebber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8956704/publications.pdf>

Version: 2024-02-01

48  
papers

2,071  
citations

411340  
20  
h-index

286692  
43  
g-index

50  
all docs

50  
docs citations

50  
times ranked

3478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-Reported Bowel, Urinary, and Sexual Outcomes After Laparoscopic-Assisted Resection or Open Resection for Rectal Cancer. <i>Annals of Surgery</i> , 2023, 277, 449-455.	2.1	7
2	The use of proxies and proxy-reported measures: a report of the international society for quality of life research (ISOQOL) proxy task force. <i>Quality of Life Research</i> , 2022, 31, 317-327.	1.5	10
3	Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	7
4	Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma. <i>BMC Cancer</i> , 2022, 22, 276.	1.1	1
5	Knowledge translation concerns for the CONSORT-PRO extension reporting guidance: a review of reviews. <i>Quality of Life Research</i> , 2022, 31, 2939-2957.	1.5	7
6	Improving the patient-reported outcome sections of clinical trial protocols: a mixed methods evaluation of educational workshops. <i>Quality of Life Research</i> , 2022, , 1.	1.5	1
7	Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1910.	3.8	23
8	TROG 14.04: Multicentre Study of Feasibility and Impact on Anxiety of DIBH in Breast Cancer Patients. <i>Clinical Oncology</i> , 2022, , .	0.6	0
9	The need for ethical guidance for the use of patient-reported outcomes in research and clinical practice. <i>Nature Medicine</i> , 2021, 27, 572-573.	15.2	9
10	How is quality of life defined and assessed in published research?. <i>Quality of Life Research</i> , 2021, 30, 2109-2121.	1.5	40
11	United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument. <i>Medical Decision Making</i> , 2021, 41, 485-501.	1.2	12
12	An Updated Systematic Review of Quantitative Studies Assessing Anxiety, Depression, Fear of Cancer Recurrence or Psychological Distress in Testicular Cancer Survivors. <i>Cancer Management and Research</i> , 2021, Volume 13, 3803-3816.	0.9	15
13	SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. <i>BMJ Open</i> , 2021, 11, e045105.	0.8	65
14	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , 2021, 24, 862-873.	0.1	14
15	Patient-Reported Outcomes Associated with Treatments for Testicular Cancer: A Systematic Review. <i>Patient Related Outcome Measures</i> , 2021, Volume 12, 129-171.	0.7	10
16	â€ˆGive Us The Tools!â€™: development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension. <i>BMJ Open</i> , 2021, 11, e046450.	0.8	8
17	International perspectives on suboptimal patientâ€™reported outcome trial design and reporting in cancer clinical trials: A qualitative study. <i>Cancer Medicine</i> , 2021, 10, 5475-5487.	1.3	11
18	Patient-reported outcomes and localized prostate cancer management. <i>Nature Reviews Urology</i> , 2020, 17, 257-258.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Survivorship Care Plans in Cancer: A Meta-Analysis and Systematic Review of Care Plan Outcomes. <i>Oncologist</i> , 2020, 25, e351-e372.	1.9	101
20	U.K. utility weights for the <scp>EORTC QLUâ€C10D</scp>. <i>Health Economics (United Kingdom)</i> , 2019, 28, 1385-1401.	0.8	30
21	The <scp>EORTC</scp> Quality of Life Questionnaire for cancer patients ( <scp>QLQ</scp> â€C30): Australian general population reference values. <i>Medical Journal of Australia</i> , 2019, 210, 499-506.	0.8	38
22	Patient, client, consumer, survivor or other alternatives? A scoping review of preferred terms for labelling individuals who access healthcare across settings. <i>BMJ Open</i> , 2019, 9, e025166.	0.8	43
23	Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1170-1178.	3.0	76
24	Trials with proxy-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). <i>Quality of Life Research</i> , 2019, 28, 955-962.	1.5	2
25	Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 483.	3.8	507
26	Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPIC study qualitative protocol. <i>BMJ Open</i> , 2018, 8, e017282.	0.8	6
27	The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. <i>Contemporary Clinical Trials Communications</i> , 2018, 9, 23-32.	0.5	23
28	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018, 36, 225-238.	1.7	77
29	A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data. <i>Clinical Trials</i> , 2018, 15, 95-106.	0.7	15
30	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 353-367.	0.7	295
31	Health-Related Quality of Life in Cancer. , 2018, , 109-125.		2
32	Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). <i>Quality of Life Research</i> , 2018, 27, 2581-2591.	1.5	25
33	A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e81.	1.0	7
34	What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?. <i>Breast Cancer</i> , 2017, 24, 720-729.	1.3	13
35	Treatment decision-making in ductal carcinoma in situ: A mixed methods systematic review of womenâ€™s experiences and information needs. <i>Patient Education and Counseling</i> , 2017, 100, 1654-1666.	1.0	12
36	Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension. <i>Quality of Life Research</i> , 2017, 26, 1427-1437.	1.5	42

#	ARTICLE	IF	CITATIONS
37	Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e381-e388.	0.7	10
38	A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. <i>Journal of Patient-Reported Outcomes</i> , 2017, 1, 5.	0.9	23
39	The Impact of Cancer on Psychological and Social Outcomes. <i>Australian Psychologist</i> , 2016, 51, 89-99.	0.9	40
40	Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. <i>BMJ Open</i> , 2016, 6, e012863.	0.8	15
41	The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. <i>Quality of Life Research</i> , 2016, 25, 2457-2465.	1.5	37
42	Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. <i>BMJ Open</i> , 2016, 6, e010938.	0.8	87
43	Mode of administration does not cause bias in patient-reported outcome results: a meta-analysis. <i>Quality of Life Research</i> , 2016, 25, 559-574.	1.5	87
44	Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation. <i>European Journal of Cancer</i> , 2016, 56, 144-161.	1.3	36
45	International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. <i>Quality of Life Research</i> , 2016, 25, 359-362.	1.5	19
46	Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers. <i>PLoS ONE</i> , 2014, 9, e110216.	1.1	73
47	Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 865-873.	1.2	30
48	Systematic Evaluation of the Patient-Reported Outcome (PRO) Content of Clinical Trial Protocols. <i>PLoS ONE</i> , 2014, 9, e110229.	1.1	58